Nektar Therapeutics Research and Development in Process
Nektar Therapeutics (NKTR) reported Research and Development in Process of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-05-10
- Nektar Therapeutics research and development in process for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics research and development in process for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics research and development in process for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics research and development in process for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics research and development in process for fiscal 2022 was $4.95M, a 70.36% decline from fiscal 2021.
- Nektar Therapeutics research and development in process for fiscal 2021 was $16.70M.
- Nektar Therapeutics research and development in process for fiscal 2020 was $0.00.
- Nektar Therapeutics research and development in process for fiscal 2019 was $0.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-05-10 | $0.00 derived: sum of 3 quarters · filed 2023-05-10 | $0.00 derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $4.95M 10-K · filed 2023-02-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $4.95M 10-Q · filed 2022-11-04 | $10.16M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $4.95M 10-Q · filed 2022-08-05 | $10.16M derived: sum of 3 quarters · filed 2023-05-10 | $15.86M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-03-31 | $4.95M 10-Q · filed 2023-05-10 | $10.16M derived: sum of 2 quarters · filed 2023-05-10 | $15.86M derived: sum of 3 quarters · filed 2023-05-10 | $19.41M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $5.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $10.91M derived: sum of 2 quarters · filed 2023-02-28 | $14.46M derived: sum of 3 quarters · filed 2023-02-28 | $16.70M 10-K · filed 2023-02-28 |
| 2021-09-30 | $5.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $9.25M derived: sum of 2 quarters · filed 2022-11-04 | $11.50M 10-Q · filed 2022-11-04 | $11.50M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $3.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $5.79M 10-Q · filed 2022-08-05 | $5.79M derived: sum of 3 quarters · filed 2023-02-28 | $5.79M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $2.25M 10-Q · filed 2022-05-06 | $2.25M derived: sum of 2 quarters · filed 2023-02-28 | $2.25M derived: sum of 3 quarters · filed 2023-02-28 | $2.25M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |